Question Number: 322
PDR Number: SQ22-000699
Date Submitted: 21/11/2022
Department or Body: Department of Health
To 31 October 2022, $331 million has been spent on COVID-19 oral antiviral treatments, Lagevrio® (molnupiravir) and Paxlovid® (nirmatrelvir and ritonavir). Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme data sourced from: http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp.